Polypharmacy among adult and older adult users of primary care services delivered through the Unified Health System in Minas Gerais, Brazil

References

• Johnell K. The controversies surrounding polypharmacy in old age – where are we? Expert Rev Clin Pharmacol. 2018;11(9):825–827.
   PubMed Web of Science ®Google Scholar
• Slater N, White S, Venables R, et al. Factors associated with polypharmacy in primary care: a cross-sectional analysis of data from the English longitudinal study of Ageing (ELSA). BMJ Open. 2018;8(3):e020270.
   PubMed Web of Science ®Google Scholar
• Payne RA. The epidemiology of polypharmacy. Clin Med (Lond). 2016;16(5):465–469.
   PubMed Web of Science ®Google Scholar
• Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012;65(9):989–995.
   PubMed Web of Science ®Google Scholar
• Burt J, Elmore N, Campbell SM, et al., Developing a measure of polypharmacy appropriateness in primary care: systematic review and expert consensus study. BMC Med. 2018;16(1): 91. .
   PubMedGoogle Scholar
• Kantor ED, Rehm CD, Haas JS, et al. Trends in prescription drug use among adults in the United States from 1999–2012. JAMA. 2015;314(17):1818–1831.
   PubMed Web of Science ®Google Scholar
• Guthrie B, Makubate B, Hernandez-Santiago V, et al. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010. BMC Med. 2015;13(74):1–10.
   PubMedGoogle Scholar
• Moriarty F, Hardy C, Bennett K, et al. Trends and interaction of polypharmacy and potentially inappropriate prescribing in primary care over 15 years in Ireland: a repeated cross-sectional study. BMJ Open. 2015;5(9):e008656.
   PubMed Web of Science ®Google Scholar
• Cadogan CA, Ryan C, Hughes CM. Appropriate polypharmacy and medicine safety: when many is not too many. Drug Saf. 2016;39:109–116.
   PubMed Web of Science ®Google Scholar
• Morin L, Johnell K, Laroche ML, et al. The epidemiology of polypharmacy in older adults: register-based prospective cohort study. Clin Epidemiol. 2018;10:289–298.
   PubMed Web of Science ®Google Scholar
• Ramos LR, Tavares NUL, Bertoldi AD, et al. Polypharmacy and polymorbidity in older adults in Brazil: a public health challenge. Rev Saude Publica. 2016;50(sup.2:9s):1s–12s.
   PubMedGoogle Scholar
• Carvalho JN, Roncalli AG, Cancela MC, et al. Prevalence of multimorbidity in the Brazilian adult population according to socioeconomic and demographic characteristics. PloS One. 2017;12(4):e0174322.
   PubMed Web of Science ®Google Scholar
• Aubert CE, Streit S, Costa BR, et al. Polypharmacy and specific comorbidities in university primary care settings. Eur J Intern Med. 2016;35:35–42.
   PubMed Web of Science ®Google Scholar
• Bourgeois FT, Shannon MW, Valim C, et al. Adverse drug events in the outpatient setting: an 11-year national analysis. Pharmacoepidemiol Drug Saf. 2010;19(9):901–910.
   PubMed Web of Science ®Google Scholar
• Guthrie B, McCowan, Davey P, et al. High risk prescribing in primary care patients particularly vulnerable to adverse drug events: cross sectional population database analysis in Scottish general practice. BMJ. 2011;324:d3514.
   Google Scholar
• Lavan AM, Gallagher P. Predicting risk of adverse drug reactions in older adults. Ther Adv Drug Saf. 2016;7(1):11–22.
   PubMed Web of Science ®Google Scholar
• Mira JJ, Orozco-Beltrán D, Pérez-Jover V, et al. Physician patient communication failure facilitates medication errors in older polymedicated patients with multiple comorbidities. Fam Pract. 2013;30(1):56–63.
   PubMed Web of Science ®Google Scholar
• Hovstadius B, Petersson G. The impact of increasing polypharmacy on prescribed drug expenditure- A register-based study in Sweden 2005–2009. Health Policy. 2013;109(2):166–174.
   PubMed Web of Science ®Google Scholar
• Maher RL, Hanlon JT, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):1–11.
   PubMed Web of Science ®Google Scholar
• Gnjidic D, Tinetti M, Allore HG. Assessing medication burden and polypharmacy: finding the perfect measure. Expert Rev Clin Pharmacol. 2017;10(4):345–347.
   PubMed Web of Science ®Google Scholar
• Grimmsmann T, Himmel W. Polypharmacy in primary care practices: an analysis using a large health insurance database. Pharmacoepidemiol Drug Saf. 2009;18(12):1206–1213.
   PubMed Web of Science ®Google Scholar
• Nascimento RCRM, Álvares J, Guerra Júnior AA, et al. Polypharmacy: a challenge for the primary health care of the Brazilian Unified Health System. Rev Saude Publica. 2017;51(supl 2:19s):1s–12s.
   PubMedGoogle Scholar
• Álvares J, Alves MCGP, Escuder MML, et al. National survey on access, use and promotion of rational use of medicines: methods. Rev Saude Publica. 2017;51(Supl.2:4s):1s–9s.
   PubMedGoogle Scholar
• Barbosa MM, Garcia MM, Nascimento RCRM, et al. Infrastructure evaluation of pharmaceutical services in the national health system of Minas Gerais. Cien Saude Colet. 2017;22(8):2475–2486.
   PubMed Web of Science ®Google Scholar
• WHO Collaborating Centre for drugs statistics methodology. Anatomical therapeutic chemical classification - ATC code. Oslo; 2018 [cited 2018 jan 8]. Available from: http://www.whocc.no/atc_ddd_index/.
   Google Scholar
• American Geriatrics Society. 2012 updated beers criteria for potentially inappropriate medication use in older adults: the American geriatrics society 2012 beers criteria update expert panel. J Am Geriatr Soc. 2012;60(4):616–631.
   PubMed Web of Science ®Google Scholar
• Neves SJF, Marques APO, Leal MCC, et al. Epidemiology of medication use among the elderly in an urban area of northeastern Brazil. Rev Saude Publica. 2013;47(4):759–768.
   PubMed Web of Science ®Google Scholar
• Almeida NA, Reiners AAO, Azevedo RCS, et al. Prevalence of and factors associated with polypharmacy among elderly persons resident in the community. Rev Bras Geriatr Gerontol. 2017;20(1):138–148.
   Google Scholar
• Silveira EA, Dalastra L, Pagotto V. Polypharmacy, chronic diseases and nutritional markers in community-dwelling older. Rev Bras Epidemiol. 2014;17(4):818–829.
   PubMedGoogle Scholar
• Rozenfeld S, Fonseca MJM, Acurcio FA. Drug utilization and polypharmacy among the elderly: a survey in Rio de Janeiro City, Brazil. Rev Panam Salud Publica. 2008;23(1):34–43.
   PubMed Web of Science ®Google Scholar
• Carvalho MFC, Romano-Lieber NS, Bergsten-Mendes G, et al. Polypharmacy among the elderly in the city of São Paulo, Brazil – SABE study. Rev Bras Epidemiol. 2012;15(4):817–827.
   PubMedGoogle Scholar
• Charlesworth CJ, Smit E, Lee DSH, et al. Polypharmacy among adults aged 65 years and older in the United States:1988–2010. J Gerontol A Biol Med Sci. 2015;70(8):989–995.
   PubMed Web of Science ®Google Scholar
• Skinner M. A literature review: polypharmacy protocol for primary care. Geriatr Nurs. 2015;36(5):367–371.
   PubMed Web of Science ®Google Scholar
• DeRhodes KH. The dangers of ignoring the Beers criteria- The prescribing cascade. JAMA Intern Med. 2019;179(7):863–864.
   PubMed Web of Science ®Google Scholar
• Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research and medical education: a cross-sectional study. Lancet. 2012;380(9836):37–43.
   PubMed Web of Science ®Google Scholar
• Fleg JL, Aronow WS, Frishman WH. Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol. 2011;8(1):13–28.
   PubMed Web of Science ®Google Scholar
• Agborsangaya CB, Lau D, Lahtinen M, et al. Multimorbidity prevalence and patterns across socioeconomic determinants: a cross-sectional survey. BMC Public Health. 2012;12:201.
   PubMed Web of Science ®Google Scholar
• Wastesson JW, Morin L, Tan ECK, et al. An update on the clinical consequences of polypharmacy in older adults: a narrative review. Expert Opin Drug Saf. 2018;17(12):1185–1196.
   PubMed Web of Science ®Google Scholar
• Castioni J, Marques-Vidal P, Abolhassani N, et al. Prevalence and determinants of polypharmacy in Switzerland: data from the CoLaus study. BMC Health Serv Res. 2017;17(1):840.
   PubMedGoogle Scholar
• Neves S, Marques APO, Leal MCC, et al. Epidemiology of medication use among the elderly in an urban area of northeastern Brazil. Rev Saúde Pública. 2013;47(4):1–10.
   Web of Science ®Google Scholar
• Negrini ELD, Nascimento CF, Silva A, et al. Elderly persons who live alone in Brazil and their lifestyle. Rev Bras Geriatr Gerontol. [Internet].. 2018;21(5):523–531.
   Google Scholar
• Gallacher KL, Batty GD, McLean G, et al. Stroke, multimorbidity and polypharmacy in a nationally representative sample of 1,424,378 patients in Scotland: implications for treatment burden. BMC Med. 2014;12:151.
   PubMed Web of Science ®Google Scholar
• Martinez-Gomez D, Guallar-Castillon P, Higueras-Fresnillo S, et al. A healthy lifestyle attenuates the effect of polypharmacy on total and cardiovascular mortality: a national prospective cohort study. Sci Rep. 2018;8(1):12615.
   PubMedGoogle Scholar
• Meschia JF, Bushnell CD, Boden-Albala B, et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American heart association. American stroke association. Stroke. 2014;45(12):3754–3832.
   PubMed Web of Science ®Google Scholar
• Silva MRR, Diniz LM, Santos JBR, et al. Drug utilization and factors associated with polypharmacy in individuals with diabetes mellitus in Minas Gerais, Brazil. Cien Saude Colet. 2018;23(8):2565–2574.
   PubMed Web of Science ®Google Scholar
• Poluzzi E, Korhonen MJ. Drug utilization research in the area of cardiovascular medicines. In: Elseviers M [and 12 others], editor. Drug utilization research: methods and applications. Chichester, West Sussex: Wiley-Blackwell; 2016. p. 284–293.
   Google Scholar
• Faludi AA, Izar MCO, Saraiva JFK, et al. Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose- 2017 [The 2017 Updated Brazilian guideline for Dyslipidemia and Atherosclerosis prevention]. Arq Bras Cardiol. 2017;109(2Supl.1):1–76. Portuguese
   Google Scholar
• Nascimento RCRM, Guerra Júnior AA, Álvares J, et al. Statin use in Brazil: findings and implications. Curr Med Res Opin. 2018;34(10):1809–1817.
   PubMed Web of Science ®Google Scholar
• Holvast F, Hattem BAV, Sinnige J, et al. Late-life depression and the association with multimorbidy and polypharmacy: a cross-sectional study. Fam Pract. 2017;34(5):539–545.
   PubMed Web of Science ®Google Scholar
• Aziz R, Steffens DC. What are the causes of late-life depression? Psychiatr Clin North Am. 2013;36(4):497–516.
   PubMed Web of Science ®Google Scholar
• Grochtdreis T, Brettschneider C, Bjerregaard F, et al. Cost-effectiveness analysis of collaborative treatment of late-life depression in primary care (GermanIMPACT). Eur Psychiatry. 2019;57:10–18.
   PubMed Web of Science ®Google Scholar
• Koren G, Nordon G, Radinsky K, et al. Clinical pharmacology of old age. Expert Rev Clin Pharmacol. 2019;12(8):749–755.
   PubMed Web of Science ®Google Scholar
• Holloway KA. Combating inappropriate use of medicines. Expert Rev Clin Pharmacol. 2011;4(3):335–348.
   PubMedGoogle Scholar